Dulaglutide

What it is & what research shows

Study example available

Dulaglutide is listed as a peptide in the metabolism section of this catalog. Also indexed as Trulicity. A source-verified explanation of its mechanism and uses has not yet been completed here; the catalog category is not evidence of benefit.

One selected study: SUSTAIN 7 was a randomized, open-label phase 3b trial comparing weekly semaglutide with dulaglutide; HbA1c and body weight were assessed at week 40. Participants were adults with type 2 diabetes inadequately controlled on metformin alone. A verified dose and schedule have not yet been added to this study summary. At the lower-dose comparison, body weight fell by 4.6 kg with semaglutide and 2.3 kg with dulaglutide. The study was open-label. Gastrointestinal disorders were the most common reason for discontinuation, and six fatalities occurred across the four groups. [2.1]

Studied methods, not dosing advice. Selected evidence, not a complete literature review or formal quality appraisal. Read the study summary

Sources & reading scope

[2.1] Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial.Human · Abstract summarized · not a full-paper review

By PED Evidence

Source scope is listed with each reference. Prepared by PED Evidence with AI assistance. Independent clinician review has not been completed. Review standards

Evidence summarized on PED Evidence

2 completed summaries

2 human-study reports

1 randomized-trial candidates

1 safety-topic reports

These counts describe completed summaries on this site, not the size of the full literature. Publications can share participants; design labels are discovery metadata, not appraisals.

Filter, save and compare Dulaglutide studies →

More about Dulaglutide: identity, safety & reference details

PeptideMetabolism

Primary research area: Emerging research
Regulatory status: Research status varies
Evidence level: Evidence level not yet characterized
Primary mechanism: Mechanism not yet characterized

Reference profile incomplete · Coverage varies by section

Also known as Trulicity

Start with the research

An outcome-specific synthesis has not been prepared for this compound. This is a coverage gap, not evidence that it has no effect.

Open studies and trial records

Uses & research: Uses have not been independently checked for this profile. Browse the original studies to see the conditions and populations investigated.
Known half-life: No source-verified value in this profile yet. A treatment schedule or duration of an effect is not a drug half-life.
Half-life describes how quickly the measured drug concentration falls by half. It does not set a dosing interval.
Evidence & important limits: A catalog entry does not establish effectiveness, safety or approval. Study findings and quality appraisal remain separate.

Safety & evidence boundaries

Source-specific information, not a personal safety clearance or monitoring plan.

A compound-specific safety synthesis is not available here yet. Lack of listed adverse effects does not establish safety.

Explore safety questions by system

These are literature filters, not claims that this compound causes each effect. A keyword match is not a confirmed adverse reaction.

Heart, blood pressure & lipids Liver injury Kidney function Glucose effects Reproductive & endocrine effects Mood & sleep Adverse effects & interactions

Interactions, rare harms, long-term effects and reversibility require separate evidence. Do not infer they are absent when the sources here do not address them.

Identity, names & formulations

Canonical compound: Dulaglutide · dulaglutide

Searchable names: Trulicity

Names share a parent research page. Different esters, salts, routes and brands are not assumed to have the same half-life, indication or exposure.

Combination evidence stays attached to the studied combination. It is not automatically assigned to each ingredient.

Understand the evidence types

Read the model and design first, then the population, outcome and limitations. These categories describe evidence, not a best-compound ranking.

Randomized human trials: Compare assigned interventions. Randomization does not by itself establish low bias or relevance to every population.
Controlled human studies: Use a comparison group; allocation and confounding still matter.
Prospective human research: Follows participants forward. It may be observational or interventional, so this is not a separate quality grade.
Observational human research: Describes associations. Confounding can explain differences.
Case reports and series: Useful for unusual events and safety signals, not reliable rates or effect sizes.
Animal research: Can test biology and function in a living model. Human exposure, benefit and safety remain separate questions.
Cell and tissue research: Tests responses in a preparation, including human-derived cells. It is not a human participant trial.
Mechanistic and computational evidence: Helps explain or predict a pathway; predictions need experimental and clinical testing.
Anecdotal reports: Self-reported experiences can generate questions. Product identity, selection bias and other interventions may be uncontrolled.

Systematic reviews synthesize studies and depend on their quality. Preprint status and abstract versus full-paper reading are separate labels. Citation popularity measures attention, not reliability. A study summary is not a formal quality appraisal.

Browse all studies

Research outcomeResearch model

Study model describes the source. Confidence depends on methods, replication, population and outcome.

Loading compound research…

Dulaglutide study summaries

Human-first reading order. Intervention candidates are distinguished from background mentions in the library.